| scholarly article | Q13442814 |
| P2093 | author name string | Takeshi Saito | |
| Akihiro Nakamoto | |||
| Akira Namera | |||
| Maho Kawamura | |||
| Masataka Nagao | |||
| P2860 | cites work | Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry | Q28212734 |
| Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones | Q28249380 | ||
| Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry | Q28292326 | ||
| Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS | Q28297761 | ||
| Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part II: Color test and TLC | Q31157362 | ||
| Identification and characterization of the new designer drug 4'-methylethcathinone (4-MEC) and elaboration of a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening method for seven different methcathinone analogs | Q33874959 | ||
| Validation of the only commercially available immunoassay for synthetic cathinones in urine: Randox Drugs of Abuse V Biochip Array Technology | Q33934379 | ||
| 3,4-Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry | Q34115248 | ||
| Analyses of second-generation 'legal highs' in the UK: initial findings. | Q34129831 | ||
| Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine | Q34179558 | ||
| Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States | Q34206558 | ||
| Prevalence of new psychoactive substances: A retrospective study in hair | Q34270004 | ||
| Synthetic cannabinoids in "spice-like" herbal blends: first appearance of JWH-307 and recurrence of JWH-018 on the German market | Q34285144 | ||
| Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction | Q34287774 | ||
| Ring positional differentiation of isomeric N-alkylated fluorocathinones by gas chromatography/tandem mass spectrometry | Q34297033 | ||
| Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results | Q34325173 | ||
| Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22 | Q34421975 | ||
| 3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures | Q34429666 | ||
| Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search | Q34607414 | ||
| New designer drug alpha-pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques | Q34951585 | ||
| K2 toxicity: fatal case of psychiatric complications following AM2201 exposure | Q35057032 | ||
| Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH-018 and JWH-073 in human urine | Q35164115 | ||
| Death following recreational use of designer drug "bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV). | Q36548946 | ||
| Use of SPME-HS-GC-MS for the analysis of herbal products containing synthetic cannabinoids. | Q36727502 | ||
| Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry | Q37658304 | ||
| Mephedrone (4-methylmethcathinone): what is new in our understanding of its use and toxicity | Q38008088 | ||
| New challenges and innovation in forensic toxicology: focus on the "New Psychoactive Substances". | Q38075223 | ||
| Methylenedioxypyrovalerone ("bath salts"), related death: case report and review of the literature | Q38119006 | ||
| Synthetic cannabinoids: analysis and metabolites. | Q38177548 | ||
| Analysis of Synthetic Cannabinoids in Botanical Material: A Review of Analytical Methods and Findings. | Q38557647 | ||
| Psychoactive substances--some new, some old: a scan of the situation in the U.S. | Q39329780 | ||
| Identification of substituted cathinones: 3,4-Methylenedioxy derivatives by high performance liquid chromatography-quadrupole time of flight mass spectrometry | Q39432357 | ||
| Three fatal intoxications due to methylone | Q40286882 | ||
| New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland | Q42743410 | ||
| Mephedrone (4-methylmethcathinone)-related deaths | Q42744621 | ||
| A case of extreme agitation and death after the use of mephedrone in The Netherlands | Q42758489 | ||
| The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland | Q42946688 | ||
| Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry | Q43105766 | ||
| Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens | Q43575688 | ||
| Distribution of methylone in four postmortem cases | Q43666311 | ||
| Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry | Q43891404 | ||
| Analysis of MDPV in blood--determination and interpretation | Q44006688 | ||
| Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry | Q44349023 | ||
| Fragmentation pathways of drugs of abuse and their metabolites based on QTOF MS/MS and MS(E) accurate-mass spectra. | Q44453727 | ||
| Presence and composition of cathinone derivatives in drug samples taken from a drug test service in Spain (2010-2012). | Q44665582 | ||
| Fatal mephedrone intoxication--a case report | Q45067994 | ||
| Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. | Q45105082 | ||
| Deaths involving methylenedioxypyrovalerone (MDPV) in Upper East Tennessee | Q45120474 | ||
| Simultaneous quantification of 28 synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry | Q45219952 | ||
| The stability of four designer drugs: MDPV, mephedrone, BZP and TFMPP in three biological matrices under various storage conditions | Q45764870 | ||
| Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. | Q45962466 | ||
| Postmortem tissue distribution of MDPV following lethal intoxication by "bath salts". | Q46004696 | ||
| Cross-reactivity of designer drugs, including cathinone derivatives, in commercial enzyme-linked immunosorbent assays | Q46187150 | ||
| Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis | Q46456473 | ||
| The emergence and analysis of synthetic cannabinoids | Q47794557 | ||
| A mixed MDPV and benzodiazepine intoxication in a chronic drug abuser: determination of MDPV metabolites by LC-HRMS and discussion of the case | Q47817715 | ||
| "Legal highs"--toxicity in the clinical and medico-legal aspect as exemplified by suicide with bk-MBDB administration | Q48670180 | ||
| Analysis of 4-MEC in biological and non-biological material--three case reports | Q50056262 | ||
| Detection of buphedrone in biological and non-biological material--two case reports | Q50058343 | ||
| Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. | Q50467281 | ||
| Driving under the influence of synthetic cannabinoids ("Spice"): a case series. | Q51026124 | ||
| Quadrupole-time-of-flight mass spectrometry screening for synthetic cannabinoids in herbal blends. | Q51808092 | ||
| Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. | Q52301471 | ||
| Simultaneous analysis of synthetic cannabinoids in the materials seized during drug trafficking using GC-MS. | Q53351420 | ||
| 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? | Q55051416 | ||
| Patterns of synthetic cannabinoid use in Australia. | Q55056749 | ||
| Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist | Q55877584 | ||
| Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, | Q56460366 | ||
| New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer dr | Q56523074 | ||
| The characterization of some 3,4-methylenedioxycathinone (MDCATH) homologs | Q56553418 | ||
| Structural characterization of cathinone-type designer drugs by EI mass spectrometry | Q56607872 | ||
| Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products | Q56609546 | ||
| Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid-chromatography–electrospray tandem mass spectrometry | Q56767430 | ||
| Intoxication Delirium following Use of Synthetic Cathinone Derivatives | Q58161758 | ||
| Identification and structural characterization of the synthetic cannabinoid 3-(1-adamantoyl)-1-pentylindole as an additive in ‘herbal incense’ | Q59179000 | ||
| Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques | Q59179004 | ||
| Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples | Q59179011 | ||
| In silico and in vitro metabolism studies support identification of designer drugs in human urine by liquid chromatography/quadrupole-time-of-flight mass spectrometry | Q61037219 | ||
| [A new designer drug: methylone related death] | Q83409357 | ||
| Detection of JWH-018 and JWH-073 by UPLC-MS-MS in postmortem whole blood casework | Q83646003 | ||
| LC-MS/MS method for the quantitation of metabolites of eight commonly-used synthetic cannabinoids in human urine--an Australian perspective | Q83947389 | ||
| Identification of naphthoylindoles acting on cannabinoid receptors based on their fragmentation patterns under ESI-QTOFMS | Q84108905 | ||
| Identification of synthetic cannabinoids in herbal incense blends in the United States | Q84627915 | ||
| Determination of 22 synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry | Q84629641 | ||
| Development and validation of a liquid chromatography-tandem mass spectrometry method for the identification and quantification of JWH-018, JWH-073, JWH-019, and JWH-250 in human whole blood | Q84837090 | ||
| High-throughput bioanalytical method for analysis of synthetic cannabinoid metabolites in urine using salting-out sample preparation and LC-MS/MS | Q85444589 | ||
| Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective | Q85963858 | ||
| LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows | Q86499164 | ||
| Acute intoxication by synthetic cannabinoids--four case reports | Q86838249 | ||
| Blood synthetic cannabinoid concentrations in cases of suspected impaired driving | Q87290337 | ||
| A liquid chromatography-mass spectrometry method based on class characteristic fragmentation pathways to detect the class of indole-derivative synthetic cannabinoids in biological samples | Q87360852 | ||
| Analytical differentiation of 1-alkyl-3-acylindoles and 1-acyl-3-alkylindoles: isomeric synthetic cannabinoids | Q87417464 | ||
| A structure-reactivity relationship driven approach to the identification of a color test protocol for the presumptive indication of synthetic cannabimimetic drugs of abuse | Q87445511 | ||
| Testing for designer stimulants: metabolic profiles of 16 synthetic cathinones excreted free in human urine | Q87518537 | ||
| Quantitative analysis of 3,4-dimethylmethcathinone in blood and urine by liquid chromatography-tandem mass spectrometry in a fatal case | Q87780354 | ||
| Postmortem distribution of α-pyrrolidinobutiophenone in body fluids and solid tissues of a human cadaver | Q88007735 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| AM-694 | Q4652501 | ||
| P304 | page(s) | 175-194 | |
| P577 | publication date | 2015-03-06 | |
| P1433 | published in | Forensic Toxicology | Q15724497 |
| P1476 | title | Comprehensive review of the detection methods for synthetic cannabinoids and cathinones | |
| P478 | volume | 33 |
| Q39343163 | A Fast and Comprehensive Analysis of 32 Synthetic Cannabinoids Using Agilent Triple Quadrupole LC-MS-MS. |
| Q34540515 | Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project |
| Q34509038 | Annual banned-substance review: analytical approaches in human sports drug testing |
| Q30244676 | Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker Metabolites |
| Q63416932 | Bioanalytical methods for the determination of synthetic cannabinoids and metabolites in biological specimens |
| Q97528411 | Can X-Ray Powder Diffraction Be a Suitable Forensic Method for Illicit Drug Identification? |
| Q52560349 | Cardiovascular Metabolomics. |
| Q37183077 | Chiral enantioresolution of cathinone derivatives present in "legal highs", and enantioselectivity evaluation on cytotoxicity of 3,4-methylenedioxypyrovalerone (MDPV) |
| Q55080638 | Chromogenic and Fluorogenic Probes for the Detection of Illicit Drugs. |
| Q42375440 | Clinical and epidemiological characteristics of patients with acute drug intoxication admitted to ICU. |
| Q88786653 | Collaboration of the Joint Research Centre and European Customs Laboratories for the Identification of New Psychoactive Substances |
| Q50009662 | Color Spot Test As a Presumptive Tool for the Rapid Detection of Synthetic Cathinones |
| Q38612705 | Cross-Reactive Plasmonic Aptasensors for Controlled Substance Identification |
| Q48157507 | Discrimination between closely related synthetic cannabinoids by GC-Cold-EI-MS. |
| Q51228125 | Enantioselective determination of cathinone derivatives in human hair by capillary electrophoresis combined in-line with solid-phase extraction. |
| Q98771495 | Gas Chromatography-Fourier Transform Infrared Spectroscopy for Unambiguous Determination of Illicit Drugs: A Proof of Concept |
| Q58389040 | HPLC-MS/MS combined with membrane-protected molecularly imprinted polymer micro-solid-phase extraction for synthetic cathinones monitoring in urine |
| Q34553148 | In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). |
| Q90360555 | Inhibiting Analyte Theft in Surface-Enhanced Raman Spectroscopy Substrates: Subnanomolar Quantitative Drug Detection |
| Q99629436 | Innovative engineering and sensing strategies for aptamer-based small-molecule detection |
| Q50095427 | Prediction of designer drugs: synthesis and spectroscopic analysis of synthetic cathinone analogues that may appear on the Swedish drug market |
| Q64895860 | Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians. |
| Q38836231 | Quantification of Synthetic Cathinones in Rat Brain Using HILIC-ESI-MS/MS. |
| Q49574438 | Recent Trends in Analytical Methods to Determine New Psychoactive Substances in Hair. |
| Q57888900 | Salvia divinorum: toxicological aspects and analysis in human biological specimens |
| Q55425177 | Simple screening procedure for 72 synthetic cannabinoids in whole blood by liquid chromatography-tandem mass spectrometry. |
| Q92052061 | Synthetic Cathinones: A Brief Overview of Overviews with Applications to the Forensic Sciences |
| Q26767016 | Synthetic cannabinoids 2015: An update for pediatricians in clinical practice |
| Q89728368 | Synthetic psychoactive cathinones: hypothermia and reduced lethality compared to methamphetamine and methylenedioxymethamphetamine |
| Q37146954 | The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities |
| Q49723300 | The newest cathinone derivatives as designer drugs: an analytical and toxicological review. |
Search more.